Thromboelastographic study of biomaterials

Peng, Henry T.

doi:10.1002/jbm.b.31626

Cited by 43 publications

(36 citation statements)

References 122 publications

(312 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have also been earlier studies which have shown that such assays based on PPP failed to demonstrate the effects of agents such as recombinant Factor VIIa. 13 In this study, we sought to avoid potential false negatives by using TEG which measures the entire coagulation pathway, including all redundancies, by exposing materials to whole blood and measuring subsequent clot formation. The TEG has been in existence for more than 50 years and its clinical use is well established.…”

Section: Discussionmentioning

confidence: 99%

“…Although TEG was used briefly in biomaterials in the 1970s and 1980s, its use has fallen out of favor, partly due to difficulty in sample preparation. 15,16 Recently, Peng et al 13 reviewed the use of TEG for studying the effects of biomaterials on blood coagulation. A common methodology used by researchers in the case of blood soluble and blood substitute polymers is to mix these materials with the blood and then add the polymer diluted blood in the TEG cup to measure coagulation, but this method will not work for insoluble materials such as those of most interest for medical device design.…”

Section: Introductionmentioning

confidence: 99%

“…13,14 TEG provides a comprehensive assay of the overall clotting process by measuring the rate and strength of blood clot formation. Although TEG was used briefly in biomaterials in the 1970s and 1980s, its use has fallen out of favor, partly due to difficulty in sample preparation.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Standardized methods to quantify thrombogenicity of blood‐contacting materials via thromboelastography

et al. 2011

View full text Add to dashboard Cite

Blood coagulation is the most significant complication of vascular biomaterials. A straightforward, sensitive, and standard measure of the compatibility of these materials with whole blood (hemocompatibility) is necessary to avoid coagulation. Current techniques used quantify only individual clotting components and are poor predictors of coagulation. The thromboelastograph (TEG) provides a measure of overall clot formation from whole blood. Although TEG is very common in clinical settings, its application to biomaterials is limited partly due to difficulty in sample preparation. In this protocol, whole blood samples are incubated with (1) biomaterials (tube with clamped ends) and (2) endothelial cells cultured on biomaterial surfaces (12-well plate) under controlled shearing conditions (10 rpm on rocker, at 37°C), and then the blood is transferred to the TEG to measure clot formation. TEG clearly discriminates among the R-times (time until initial clot formation) of expanded poly(tetrafluoroethylene), poly(urethane), and Tygon tubing. Marked differences in R-time are also seen when endothelial cells are cultured on various extracellular matrix proteins and proteoglycans. Thus, R-time provides a robust metric of overall thrombogenicity of biomaterials, and these procedures provide a standardized method for TEG to facilitate direct comparison among candidate biomaterials undergoing in-vitro testing.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Standardized methods to quantify thrombogenicity of blood‐contacting materials via thromboelastography

et al. 2011

View full text Add to dashboard Cite

show abstract

“…TEG is a test with time as horizontal ordinate to reflect blood clotting process and clot strength 8 . An anticoagulated whole blood sample (1 mL) and a sample to be tested (10 mg) were mixed well in a centrifuge tube and pipetted into a test cup.…”

Section: ) Thromboelastography Testmentioning

confidence: 99%

Effect of Grafted Chain Length on Hemostatic Activity of N-alkylated Chitosan

Liu¹,

Yang²,

Guan³

et al. 2018

Proceedings of the 4th Annual International Conference on Material Engineering and Application (ICMEA 2017)

View full text Add to dashboard Cite

Abstract-This study aimed to synthesize N-alkylated chitosan derivates with similar degree of substitution (DS) and alkyl groups of different carbon chain lengths via reductive alkylation, and then to compare their coagulation properties. Structural properties of the N-alkylated chitosan derivates were characterized by Fourier transform infrared spectroscopy, elemental analysis and 1 H nuclear magnetic resonance spectroscopy. Their pro-coagulant properties were evaluated by detecting whole blood clotting time and performing TEG test. Pro-coagulant mechanisms of the Nalkylated chitosan derivates were explored by detecting intracellular Ca 2+ concentration in platelets and P-selectin expression on platelets. We successfully prepared N-alkylated chitosan derivates with a DS of 32.88%-39.78%, including NACS6, NACS12 and NACS18. Our experimental findings showed that all N-alkylated chitosan derivates (NACS6, NACS12, NACS18) have outstanding procoagulant effects, and the longer alkyl chain, the better procoagulant ability. However, N-alkylated chitosan cannot activate platelets, and its procoagulant mechanism remains to be further studied in future. Based on the above results, this paper makes a conjecture about the coagulation mechanism of N-alkylation chitosan.

show abstract

“…In contrast, its use as a research tool for evaluating the effectiveness of hemostatic agents, especially those insoluble in blood, is limited [13].…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of Hemostatic Agents Using Thrombelastography

Peng¹

2016

Mater. Sci. Eng. Adv. Res

View full text Add to dashboard Cite

Hemorrhage is one of the leading causes of death in civilian and military trauma. Thrombelastography (TEG) quantitatively measures the viscoelastic changes of whole blood during clotting, from the beginning of coagulation to the end with fibrinolysis. In this study, we successfully developedand used a TEG method to compare a well-known Chinese herb medicine (i.e., Yunnan Baiyao) for hemorrhage control with other commercial hemostatic products (e.g., Celox TM and QuikClot TM ) and chitosan in the form of dry powder or dispersion. When tested in the powder form, the herbal material outperformed Celox TM as indicated by all three TEG parameters (i.e., reaction time R, clot formation rate α and maximum clot strength MA), and was comparable with QuikClot TM , but showed no exothermic effects. When tested in the dispersion form, which may be easier to use (as a spray) than in the powder form, the herbal material provided better hemostasis than the other materials, where the coagulation actions of the latter were reduced in the dispersion form. In addition, comparison among Celox TM and various types of chitosan showed the effects of physical and chemical properties of the chitosan-based biomaterials on hemostasis. The hemostatic mechanisms of these agents and their potential benefitsas an inexpensive, safe, and easily available material for hemorrhage control are discussed.

show abstract

Thromboelastographic study of biomaterials

Cited by 43 publications

References 122 publications

Standardized methods to quantify thrombogenicity of blood‐contacting materials via thromboelastography

Standardized methods to quantify thrombogenicity of blood‐contacting materials via thromboelastography

Effect of Grafted Chain Length on Hemostatic Activity of N-alkylated Chitosan

Comparative Study of Hemostatic Agents Using Thrombelastography

Contact Info

Product

Resources

About